AstraZeneca, BMS gets FDA nod for diabetes drug
09 January 2014 | Regulatory | By BioSpectrum Bureau
Farxiga (dapagliflozin)by AstraZeneca and Bristol-Myers Squibb has got the American drug regulatory nod
Singapore: AstraZeneca and Bristol-Myers Squibb have recieved U.S. Food and Drug Administration (FDA) approval for diabetes drug Farxiga (dapagliflozin).
AstraZeneca and Bristol-Myers Squibb are working in collaboration to develop and commercialize a portfolio of innovative treatment options for diabetes and related metabolic disorders that aim to provide treatment effects beyond glucose control.
